Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) - Wikidata - thesis-toulmin - TriplyDB

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

http://www.wikidata.org/entity/Q27670616

about

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes Blind prediction of HIV integrase binding from the SAMPL4 challenge Novel therapeutic strategies targeting HIV integrase Allosteric Inhibition of Human Immunodeficiency Virus Integrase Activities, Crystal Structures, and Molecular Dynamics of Dihydro-1 H -isoindole Derivatives, Inhibitors of HIV-1 Integrase 3′-Processing and strand transfer catalysed by retroviral integrasein crystallo HIV-1 Integrase Inhibitor-Inspired Antibacterials Targeting Isoprenoid Biosynthesis Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.Structural Basis of Mos1 Transposase Inhibition by the Anti-retroviral Drug Raltegravir Might dolutegravir be part of a functional cure for HIV?Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor Retroviral DNA Integration Using the Tools and Resources of the RCSB Protein Data Bank.4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors Dolutegravir: clinical efficacy and role in HIV therapy.Rous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors.Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase Retroviral integrase proteins and HIV-1 DNA integration Retroviral Integrase Structure and DNA Recombination Mechanism The role of dolutegravir in the management of HIV infection The allosteric HIV-1 integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome MK-0536 inhibits HIV-1 integrases resistant to raltegravir Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.Probing chelation motifs in HIV integrase inhibitors Interactions of Prototype Foamy Virus Capsids with Host Cell Polo-Like Kinases Are Important for Efficient Viral DNA Integration.B'-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase.The structural biology of HIV-1: mechanistic and therapeutic insights A targeted DNA substrate mechanism for the inhibition of HIV-1 integrase by inhibitors with antiretroviral activity.HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans

P2860

Q26778450-9F250010-8DD1-47B1-BD68-C576015CC31F Q26851997-26F038C0-5A21-4021-9D65-792DA2464498 Q26864619-4E5BB6F2-92DB-4463-8FB8-122F410E3349 Q27003960-D44CF22F-1BDB-457E-9CEA-556FCCA571BE Q27644578-155C11EB-0716-4D18-BFDA-FDF2D7BA22FF Q27674615-B21A4290-93C0-411B-9AD1-32973E96CE48 Q27679066-899D7BD1-694B-465E-9462-276DA8174FD0 Q27679484-8D6852E0-8572-43F2-B258-09C2262BD8C7 Q27680666-C0211143-CC94-413A-844D-5D5B9D60DB1D Q27681216-DFDEFEF2-47A0-4458-92E7-EE1FCE67D4EF Q28071420-F4683B9E-13C8-48FA-8E43-5E0ADBE8A5CD Q28077053-0A502FB9-B877-47F4-B850-D57B25E38E33 Q28480958-D759654D-F066-4B47-ADB2-D5AD7CE52EBE Q28534464-4555909C-0CF1-4B48-8CA9-48F1D38AD269 Q28547968-DC0A22D4-1829-4DD6-95CA-09C897FE81BA Q28596842-2C193990-985D-4642-B000-2015276C9AE6 Q31127140-A6C3C72C-A18A-4A8C-9EEA-ED82497B34F1 Q33636046-F1C0102D-2B0F-4219-BE67-1D981B4346BB Q33725024-1571CD02-F081-4C32-B206-1CD8D7FED25E Q33888602-20B90FA6-C802-47D7-A7C2-093CAB4FBE37 Q33900890-8F050FD3-DFD1-49B7-8BE3-D804DA4A9DCC Q33963458-6276CADB-9274-4985-BA47-FD9F94F32D2B Q34059575-3B48D77C-27DC-41F2-BE81-7CEFBE5C4999 Q34193340-7D0D454F-6AC7-49D6-9FD1-357FEE53416E Q34372481-8C137632-B3F2-4C65-BC3F-6AFEC0E94B5C Q34597650-25267068-CC8D-4593-970E-3E710C1833E3 Q34643561-FC3C13D0-0CE7-468E-908D-9295CF2780B6 Q34668065-B468FB95-94CE-4420-9548-349B54EE97ED Q35121450-3B3A8271-E0DF-49B4-8753-FD2E24BB16F7 Q35215018-F83C64A7-21F8-4015-96E3-8C8AC4634478 Q35363825-6D8B8421-1862-4D10-8AD5-B684955E2D48 Q35666439-FA825F86-9D57-47BD-82E7-3842AC1BF104 Q35786972-76E782FD-C1E7-484A-8EC0-B36B495B81C9 Q36118484-748B912E-B19B-48E3-9271-BC21C1599C51 Q36443322-6348A181-C6A3-4106-8FAF-FD900922FA31 Q36656440-9558CB53-5F49-4224-A3A8-7DA2367A5156 Q36766768-2635D8BA-C88D-469F-837F-FBA033DEAA05 Q36812121-DAB42EFE-F3FF-477D-B329-DC5570FC0217 Q37026630-10443985-B880-4FC9-8523-903AA4D40A45 Q37036624-0F953533-D077-48FA-920D-5B6497A2F6C2

P2860

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

http://www.wikidata.org/entity/Q27670616

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@ast

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@en

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@nl

type

label

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@ast

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@en

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@nl

prefLabel

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@ast

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@en

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@nl

P1433

Q27670616-C0D9FAE3-3B8D-4A32-BA49-05D5381273CC

P1476

Q27670616-4C9A0030-D9A2-4BE8-9686-242E5BF9D325

P2093

Q27670616-272EA7AB-9BEB-4F61-AC52-A5F9ED024C12

Q27670616-6B0FDB1C-16AC-4FE4-9183-0E3C981C24E2

Q27670616-8A38CD8E-2354-47A3-86E5-D907589A0E40

Q27670616-FA89B4C2-57D4-4521-8382-024716EF4757

P2860

Q27670616-0B058853-22B2-48EC-9B2E-343677EE84B8

Q27670616-0D456B26-9FC3-4373-A813-C23F784B1A28

Q27670616-10FF24AA-B1B1-4176-953F-0407CF04DE77

Q27670616-13A3B7AF-083E-42B1-B1A8-CB2AF0FAD61C

Q27670616-174AE3A9-01B4-4C64-86B1-680CCB80FC3F

Q27670616-1D4F8533-FE2F-4091-B3BC-0F3527F64938

Q27670616-22328933-2371-4E19-98A9-0612BB382E75

Q27670616-23ED29AE-F96A-4609-A0C7-8017E3A8856F

Q27670616-24E18919-B2D3-40C0-85D3-6CB55E85AA48

Q27670616-3A5E96EB-7C05-433B-958F-048AD79960A4

P304

Q27670616-87DBBA8F-EEB7-4B1D-81E5-50F61D0DBB45

P31

Q27670616-C3821947-3F99-42E2-AED6-56FE51EF1170

P3181

Q27670616-C77D4EAF-B22D-4065-848D-D209CF64D8EC

P356

Q27670616-9A0830BC-F580-41A1-B1B9-35619F744948

P433

Q27670616-CF1C9DF5-4362-4B16-9276-BF25D2C4E6CC

P478

Q27670616-A7C1CCA0-8F1D-4AE2-9188-9D70528573D4

P50

Q27670616-3F1B4425-870D-48F4-AD31-39C383ABD556

Q27670616-404ED156-5BE7-483C-A016-502C0203A1EC

Q27670616-51B337F7-A0D9-41F7-89F3-0D2338AFA828

P577

Q27670616-8D9B1D5F-A8CA-47D5-A517-41C53997985F

P5875

Q27670616-D9D7F620-F21C-451E-82D7-D8400E588E4C

P698

Q27670616-3B85969C-F734-4FAF-98A6-20AA40E04804

P932

Q27670616-548F1551-FEC1-4E19-BBD8-88311E0516B8

P3181

P356

P1433

Molecular Pharmacology

P1476

Structural and Functional Anal ...... or Dolutegravir (S/GSK1349572)

@en

P2093

Albert Jaxa-Chamiec

http://www.w3.org/2001/XMLSchema#string

Mathieu Métifiot

http://www.w3.org/2001/XMLSchema#string

Stephen Hare

http://www.w3.org/2001/XMLSchema#string

Steven J Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor

Retroviral intasome assembly and inhibition of DNA strand transfer

Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein

A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

Functional and structural characterization of the integrase from the prototype foamy virus

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

The mechanism of retroviral integration from X-ray structures of its key intermediates

Coot: model-building tools for molecular graphics

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

P304

565-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3281962

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/MOL.111.073189

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Peter Cherepanov

Stephen H. Hughes

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51457958

http://www.w3.org/2001/XMLSchema#string

P698

21719464

http://www.w3.org/2001/XMLSchema#string

P932

3187526

http://www.w3.org/2001/XMLSchema#string